(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Bionano Genomics, Inovio Pharmaceuticals, and Lumen Technologies.

The three biggest losers today are ANGI Homeservices, Ebix, and BioSig Technologies.

Winners today

1. Bionano Genomics (BNGOW) – 24.59%

NASDAQ ended the session with Bionano Genomics rising 24.59% to $0.01 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Yearly Top and Bottom Value

Bionano Genomics’s stock is valued at $0.01 at 17:32 EST, below its 52-week high of $0.01 and way above its 52-week low of $0.01.

More news about Bionano Genomics.

2. Inovio Pharmaceuticals (INO) – 11.91%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals jumping 11.91% to $0.45 on Thursday, after five successive sessions in a row of losses. NASDAQ rose 0.12% to $13,737.99, after two sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.1%.

Volatility

Inovio Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.75%, a negative 1.29%, and a positive 4.50%.

Inovio Pharmaceuticals’s highest amplitude of average volatility was 3.75% (last week), 3.83% (last month), and 4.50% (last quarter).

Sales Growth

Inovio Pharmaceuticals’s sales growth is negative 66.8% for the present quarter and negative 58.1% for the next.

Yearly Top and Bottom Value

Inovio Pharmaceuticals’s stock is valued at $0.45 at 17:32 EST, way under its 52-week high of $2.82 and way higher than its 52-week low of $0.38.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Inovio Pharmaceuticals’s stock is considered to be overbought (>=80).

More news about Inovio Pharmaceuticals.

3. Lumen Technologies (LUMN) – 10.06%

Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as edge cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based ethernet, legacy data hosting services, and conferencing services. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. The company was incorporated in 1968 and is headquartered in Monroe, Louisiana.

NYSE ended the session with Lumen Technologies rising 10.06% to $1.92 on Thursday, after two successive sessions in a row of gains. NYSE fell 0% to $16,135.22, after two consecutive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Lumen Technologies has a trailing twelve months EPS of $-1.55.

Volatility

Lumen Technologies’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.62%, a negative 0.94%, and a positive 4.68%.

Lumen Technologies’s highest amplitude of average volatility was 2.59% (last week), 5.32% (last month), and 4.68% (last quarter).

Volume

Today’s last reported volume for Lumen Technologies is 37408800 which is 55.1% above its average volume of 24119100.

More news about Lumen Technologies.

4. BOQI International Medical (BIMI) – 9.6%

BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes varieties of products, including raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is headquartered in New York, New York.

NASDAQ ended the session with BOQI International Medical jumping 9.6% to $2.76 on Thursday while NASDAQ rose 0.12% to $13,737.99.

Earnings Per Share

As for profitability, BOQI International Medical has a trailing twelve months EPS of $-5.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -177.29%.

More news about BOQI International Medical.

5. Aeglea BioTherapeutics (AGLE) – 7.68%

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

NASDAQ ended the session with Aeglea BioTherapeutics jumping 7.68% to $0.50 on Thursday, after two successive sessions in a row of gains. NASDAQ rose 0.12% to $13,737.99, after two sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Aeglea BioTherapeutics has a trailing twelve months EPS of $-0.82.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -163.26%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 85.5%, now sitting on 1.17M for the twelve trailing months.

More news about Aeglea BioTherapeutics.

6. Novavax (NVAX) – 7.65%

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax jumping 7.65% to $7.66 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Earnings Per Share

As for profitability, Novavax has a trailing twelve months EPS of $-14.89.

Volume

Today’s last reported volume for Novavax is 12490600 which is 102.56% above its average volume of 6166200.

Volatility

Novavax’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.71%, a negative 1.31%, and a positive 4.27%.

Novavax’s highest amplitude of average volatility was 3.71% (last week), 3.66% (last month), and 4.27% (last quarter).

Moving Average

Novavax’s value is under its 50-day moving average of $7.78 and way below its 200-day moving average of $11.09.

Revenue Growth

Year-on-year quarterly revenue growth declined by 88.5%, now sitting on 1.36B for the twelve trailing months.

Previous days news about Novavax

• Novavax (nvax) Q2 earnings: taking a look at key metrics versus estimates. According to Zacks on Tuesday, 8 August, "For the quarter ended June 2023, Novavax (NVAX Quick QuoteNVAX – Free Report) reported revenue of $424.43 million, up 128.3% over the same period last year. ", "Here is how Novavax performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about Novavax.

7. Sabre Corporation (SABR) – 7.17%

Sabre Corporation, through its subsidiaries, provides software and technology solutions for the travel industry worldwide. It operates in two segments, Travel Solutions and Hospitality Solutions. The Travel Solutions segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments. This segment also provides a portfolio of software technology products and solutions through software-as-a-service (SaaS) and hosted delivery models to airlines and other travel suppliers. Its products include reservation systems for carriers, commercial and operations products, agency solutions, and data-driven intelligence solutions. The Hospitality Solutions segment provides software and solutions to hoteliers through SaaS and hosted delivery models. Sabre Corporation was incorporated in 2006 and is headquartered in Southlake, Texas.

NASDAQ ended the session with Sabre Corporation rising 7.17% to $5.45 on Thursday, following the last session’s downward trend. NASDAQ jumped 0.12% to $13,737.99, after two sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Sabre Corporation has a trailing twelve months EPS of $-1.82.

Yearly Top and Bottom Value

Sabre Corporation’s stock is valued at $5.45 at 17:32 EST, way below its 52-week high of $8.31 and way above its 52-week low of $2.99.

Sales Growth

Sabre Corporation’s sales growth is 9.2% for the present quarter and 9.5% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Sabre Corporation’s EBITDA is 125.38.

Volume

Today’s last reported volume for Sabre Corporation is 11738600 which is 51.07% above its average volume of 7770230.

More news about Sabre Corporation.

8. Catalyst Pharmaceuticals (CPRX) – 6.44%

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

NASDAQ ended the session with Catalyst Pharmaceuticals jumping 6.44% to $15.03 on Thursday, following the last session’s downward trend. NASDAQ rose 0.12% to $13,737.99, after two successive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.88.

PE Ratio

Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 17.08. Meaning, the purchaser of the share is investing $17.08 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.89%.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 1943890 which is 4.01% above its average volume of 1868920.

More news about Catalyst Pharmaceuticals.

9. Lyft (LYFT) – 6.01%

Lyft, Inc. operates a peer-to-peer marketplace for on-demand ridesharing in the United States and Canada. The company operates multimodal transportation networks that offer riders personalized and on-demand access to various mobility options. It provides Ridesharing Marketplace, which connects drivers with riders; Express Drive, a flexible car rentals program for drivers; Lyft Rentals that provides vehicles for long-distance trips; and a network of shared bikes and scooters in various cities to address the needs of riders for short trips. The company also integrates third-party public transit data into the Lyft app to offer riders various transportation options. In addition, it offers access to autonomous vehicles; centralized tools and enterprise transportation solutions, such as concierge transportation solutions for organizations; Lyft Pink subscription plans; Lyft Pass commuter programs; first-mile and last-mile services; and university safe rides programs. The company was formerly known as Zimride, Inc. and changed its name to Lyft, Inc. in April 2013. Lyft, Inc. was incorporated in 2007 and is headquartered in San Francisco, California.

NASDAQ ended the session with Lyft rising 6.01% to $11.02 on Thursday, following the last session’s downward trend. NASDAQ rose 0.12% to $13,737.99, after two consecutive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Lyft has a trailing twelve months EPS of $-4.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -204.58%.

Volatility

Lyft’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.69%, a negative 0.30%, and a positive 3.26%.

Lyft’s highest amplitude of average volatility was 5.93% (last week), 3.53% (last month), and 3.26% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 107.7% and a negative 80%, respectively.

Previous days news about Lyft

• Lyft (Lyft) beats Q2 earnings and revenue estimates. According to Zacks on Tuesday, 8 August, "While Lyft has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"

More news about Lyft.

10. MercadoLibre (MELI) – 5.62%

MercadoLibre, Inc. operates online commerce platforms in Latin America. It operates Mercado Libre Marketplace, an automated online commerce platform that enables businesses, merchants, and individuals to list merchandise and conduct sales and purchases online; and Mercado Pago FinTech platform, a financial technology solution platform, which facilitates transactions on and off its marketplaces by providing a mechanism that allows its users to send and receive payments online, as well as allows users to transfer money through their websites or on the apps. The company also offers Mercado Fondo that allows users to invest funds deposited in their Mercado Pago accounts; Mercado Credito, which extends loans to certain merchants and consumers; and Mercado Envios logistics solution that enables sellers on its platform to utilize third-party carriers and other logistics service providers, as well as fulfillment and warehousing services for sellers. In addition, it provides Mercado Libre Classifieds, an online classified listing service, where users can list and purchase motor vehicles, real estate, and services; Mercado Libre Ads, an advertising platform, which enables large retailers and brands to promote their products and services on the web; and Mercado Shops, an online storefronts solution that enables users to set-up, manage, and promote their own digital stores. The company was incorporated in 1999 and is headquartered in Montevideo, Uruguay.

NASDAQ ended the session with MercadoLibre jumping 5.62% to $1,386.41 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Earnings Per Share

As for profitability, MercadoLibre has a trailing twelve months EPS of $12.12.

PE Ratio

MercadoLibre has a trailing twelve months price to earnings ratio of 114.39. Meaning, the purchaser of the share is investing $114.39 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.06%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 35.1%, now sitting on 11.33B for the twelve trailing months.

More news about MercadoLibre.

Losers Today

1. ANGI Homeservices (ANGI) – -33.07%

Angi Inc. offers home service professionals in the United States and internationally. Its HomeAdvisor digital marketplace service connects consumers with service professionals for home repair, maintenance, and improvement projects; provides consumers with tools and resources to find local, pre-screened, and customer-rated service professionals, as well as offers online appointment booking; and connects consumers with service professionals by telephone, as well as offers several home services-related resources. The company also owns and operates Angie's List, which connects consumers with service professionals for local services through an online directory of service professionals in various service categories; and provides consumers with valuable tools, services, and content, including verified reviews, to help them research, shop, and hire for local services. In addition, it operates Handy, a platform for connecting individuals looking for household services, primarily cleaning and handyman services; Fixd Repair that offers home warranty and service; mHelpDesk, a provider of cloud-based field service software for small to mid-size businesses; and CraftJack, a third-party lead generation service that connects home service professionals with consumers looking to complete home projects; and home services marketplaces under the Travaux, MyHammer, Werkspot, MyBuilder, HomeStars, and Instapro names. As of December 31, 2020, it had a network of approximately 208,000 service professionals. The company was formerly known as ANGI Homeservices Inc. and changed its name to Angi Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Denver, Colorado. Angi Inc. is a subsidiary of IAC/InterActiveCorp.

NASDAQ ended the session with ANGI Homeservices sliding 33.07% to $2.59 on Thursday, following the last session’s downward trend. NASDAQ jumped 0.12% to $13,737.99, after two sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, ANGI Homeservices has a trailing twelve months EPS of $-0.21.

Yearly Top and Bottom Value

ANGI Homeservices’s stock is valued at $2.59 at 17:32 EST, way below its 52-week high of $5.75 and way higher than its 52-week low of $1.81.

Sales Growth

ANGI Homeservices’s sales growth is negative 27.3% for the ongoing quarter and negative 18.5% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ANGI Homeservices’s EBITDA is 65.92.

More news about ANGI Homeservices.

2. Ebix (EBIX) – -31.92%

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

NASDAQ ended the session with Ebix sliding 31.92% to $14.78 on Thursday, after three sequential sessions in a row of losses. NASDAQ jumped 0.12% to $13,737.99, after two sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $1.71.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 8.64. Meaning, the purchaser of the share is investing $8.64 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.31%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Ebix’s stock is considered to be overbought (>=80).

Moving Average

Ebix’s worth is way below its 50-day moving average of $23.35 and way under its 200-day moving average of $19.23.

Volume

Today’s last reported volume for Ebix is 3654920 which is 714.88% above its average volume of 448522.

Yearly Top and Bottom Value

Ebix’s stock is valued at $14.78 at 17:32 EST, way under its 52-week high of $30.44 and way higher than its 52-week low of $11.75.

More news about Ebix.

3. BioSig Technologies (BSGM) – -19.07%

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for catheter ablation procedures for arrhythmias. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

NASDAQ ended the session with BioSig Technologies sliding 19.07% to $0.59 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Earnings Per Share

As for profitability, BioSig Technologies has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -461.04%.

More news about BioSig Technologies.

4. Plug Power (PLUG) – -15.67%

Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including liquid green hydrogen production, storage and handling, transportation, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; Liquefaction systems; and Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York.

NASDAQ ended the session with Plug Power sliding 15.67% to $9.06 on Thursday while NASDAQ rose 0.12% to $13,737.99.

Earnings Per Share

As for profitability, Plug Power has a trailing twelve months EPS of $-1.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.43%.

Moving Average

Plug Power’s value is way below its 50-day moving average of $10.20 and way under its 200-day moving average of $12.74.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 13.3% and 36.7%, respectively.

Sales Growth

Plug Power’s sales growth is 60.3% for the present quarter and 49.9% for the next.

Previous days news about Plug Power

• Plug Power (plug) reports Q2 loss, tops revenue estimates. According to Zacks on Wednesday, 9 August, "While Plug Power has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
• Plug Power (plug) reports Q2 earnings: what key metrics have to say. According to Zacks on Wednesday, 9 August, "For the quarter ended June 2023, Plug Power (PLUG Quick QuotePLUG – Free Report) reported revenue of $260.18 million, up 72% over the same period last year. ", "Here is how Plug Power performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about Plug Power.

5. Brilliant Acquisition Corporation (BRLIW) – -14.58%

NASDAQ ended the session with Brilliant Acquisition Corporation dropping 14.58% to $0.06 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Yearly Top and Bottom Value

Brilliant Acquisition Corporation’s stock is valued at $0.06 at 17:32 EST, higher than its 52-week high of $0.06.

More news about Brilliant Acquisition Corporation.

6. SmileDirectClub (SDC) – -14.48%

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

NASDAQ ended the session with SmileDirectClub dropping 14.48% to $0.51 on Thursday, after three successive sessions in a row of losses. NASDAQ rose 0.12% to $13,737.99, after two consecutive sessions in a row of losses, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.628.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SmileDirectClub’s stock is considered to be overbought (>=80).

More news about SmileDirectClub.

7. Applied Molecular Transport (AMTI) – -13.55%

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Applied Molecular Transport sliding 13.55% to $0.27 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Earnings Per Share

As for profitability, Applied Molecular Transport has a trailing twelve months EPS of $-2.91.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -136.19%.

Yearly Top and Bottom Value

Applied Molecular Transport’s stock is valued at $0.27 at 17:32 EST, way below its 52-week high of $2.09 and way above its 52-week low of $0.21.

More news about Applied Molecular Transport.

8. Allakos (ALLK) – -9.09%

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.

NASDAQ ended the session with Allakos dropping 9.09% to $4.90 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Earnings Per Share

As for profitability, Allakos has a trailing twelve months EPS of $-1.95.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -61.2%.

Yearly Top and Bottom Value

Allakos’s stock is valued at $4.90 at 17:32 EST, way below its 52-week high of $8.73 and way above its 52-week low of $3.30.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Allakos’s EBITDA is -3.55.

Moving Average

Allakos’s value is above its 50-day moving average of $4.79 and way below its 200-day moving average of $5.78.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 46.7% and 11.3%, respectively.

More news about Allakos.

9. Canopy Growth (CGC) – -9.04%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth falling 9.04% to $0.43 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-5.4.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.11%.

Moving Average

Canopy Growth’s value is way below its 50-day moving average of $0.64 and way under its 200-day moving average of $1.99.

Yearly Top and Bottom Value

Canopy Growth’s stock is valued at $0.43 at 17:32 EST, way below its 52-week high of $4.77 and way higher than its 52-week low of $0.35.

More news about Canopy Growth.

10. Akoustis Technologies (AKTS) – -8.37%

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.

NASDAQ ended the session with Akoustis Technologies sliding 8.37% to $2.08 on Thursday while NASDAQ jumped 0.12% to $13,737.99.

Earnings Per Share

As for profitability, Akoustis Technologies has a trailing twelve months EPS of $-1.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -56.71%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 59.7%, now sitting on 23.99M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 34.6% and 50%, respectively.

Moving Average

Akoustis Technologies’s value is way below its 50-day moving average of $2.83 and way under its 200-day moving average of $3.18.

More news about Akoustis Technologies.

Stay up to date with our winners and losers daily report